202 related articles for article (PubMed ID: 20176717)
1. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
Costello-Boerrigter LC; Boerrigter G; Cataliotti A; Harty GJ; Burnett JC
Circ Heart Fail; 2010 May; 3(3):412-9. PubMed ID: 20176717
[TBL] [Abstract][Full Text] [Related]
2. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
3. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
[TBL] [Abstract][Full Text] [Related]
4. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
5. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
Chen HH; Lainchbury JG; Harty GJ; Burnett JC
Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
[TBL] [Abstract][Full Text] [Related]
6. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
7. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
Nakamura M; Sunagawa O; Kinugawa K
Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
[TBL] [Abstract][Full Text] [Related]
8. Biological actions of brain natriuretic peptide in thoracic inferior vena caval constriction.
Clavell AL; Stingo AJ; Aarhus LL; Burnett JC
Am J Physiol; 1993 Dec; 265(6 Pt 2):R1416-22. PubMed ID: 8285286
[TBL] [Abstract][Full Text] [Related]
9. Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure.
Chen HH; Cataliotti A; Schirger JA; Martin FL; Harstad LK; Burnett JC
J Am Coll Cardiol; 2009 Apr; 53(15):1302-8. PubMed ID: 19358945
[TBL] [Abstract][Full Text] [Related]
10. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.
Boerrigter G; Soergel DG; Violin JD; Lark MW; Burnett JC
Circ Heart Fail; 2012 Sep; 5(5):627-34. PubMed ID: 22891045
[TBL] [Abstract][Full Text] [Related]
11. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure.
Grantham JA; Borgeson DD; Burnett JC
Am J Physiol; 1997 Apr; 272(4 Pt 2):R1077-83. PubMed ID: 9140004
[TBL] [Abstract][Full Text] [Related]
12. Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients.
Takasu K; Miyazaki T; Negoro K; Yatsu S; Shimizu M; Murata A; Kato T; Suda S; Hiki M; Kasai T; Miyauchi K; Daida H
Int Heart J; 2017 May; 58(3):378-384. PubMed ID: 28539565
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
[TBL] [Abstract][Full Text] [Related]
14. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
15. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs.
Maack T; Marion DN; Camargo MJ; Kleinert HD; Laragh JH; Vaughan ED; Atlas SA
Am J Med; 1984 Dec; 77(6):1069-75. PubMed ID: 6239544
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
[TBL] [Abstract][Full Text] [Related]
17. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.
Watanabe K; Dohi K; Sugimoto T; Yamada T; Sato Y; Ichikawa K; Sugiura E; Kumagai N; Nakamori S; Nakajima H; Hoshino K; Machida H; Okamoto S; Onishi K; Nakamura M; Nobori T; Ito M
J Cardiol; 2012 Dec; 60(6):462-9. PubMed ID: 23068288
[TBL] [Abstract][Full Text] [Related]
18. Combination of Urinary Sodium/Creatinine Ratio and Plasma Brain Natriuretic Peptide Level Predicts Successful Tolvaptan Therapy in Patients With Heart Failure and Volume Overload.
Sato Y; Dohi K; Watanabe K; Tanimura M; Takeuchi T; Sugiura E; Sugimoto T; Kumagai N; Ogura T; Nakamori S; Fujimoto N; Yamada N; Ito M
Int Heart J; 2016; 57(2):211-9. PubMed ID: 26973271
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure.
Imamura T; Kinugawa K; Komuro I
Int Heart J; 2016; 57(1):41-6. PubMed ID: 26742881
[TBL] [Abstract][Full Text] [Related]
20. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
Imamura T; Kinugawa K; Fujino T; Inaba T; Maki H; Hatano M; Yao A; Komuro I
Circ J; 2014; 78(9):2240-9. PubMed ID: 24954239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
